NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

亞太地區的細胞治療、基因治療市場:2020年

APAC Cell & Gene Therapy Market 2020

出版商 IMAPAC PTE. LTD 商品編碼 954998
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
亞太地區的細胞治療、基因治療市場:2020年 APAC Cell & Gene Therapy Market 2020
出版日期: 2020年09月08日內容資訊: 英文 150 Pages
簡介

本報告提供亞太地區的細胞治療、基因治療市場相關調查分析,產品平台,未來的擴張計劃,使用技術,生產能力,溫度要求,製造能力,SCM的偏好等相關的系統性資訊。

目錄

第1章 簡介

  • 序文
  • 調查範圍和資料範圍
  • IMAPAC的調查手法

第2章 各企業分析

  • 企業概要
  • GMP認證
  • 設施的規模,設備,能力等
  • 擴張計劃
  • 目前產品平台
  • 開發階段
  • 生產能力
  • 平台技術
  • 產品的溫度要求
  • 提供和SCM的偏好
  • 夥伴關係、聯盟
  • 財務成果
  • 企業亮點,新聞,更新
  • 採訪

第3章 各地區的資料與分析 (中國,台灣,日本,韓國,印度,澳洲等)

  • 細胞治療、基因治療企業的分佈
  • 成為標的疾病的種類
  • 臨床試驗的階段階段
  • 同種異體 vs. 自體療法
  • 標的抗原

第4章 其他報告

  • 參考文件
  • 免責聲明
  • 關於出版社
  • 其他報告
目錄

‘APAC Cell & Gene Therapy Market 2020’ covers comprehensive information on parameters such as product pipeline, future expansion plans, technologies used, production capacity, temperature requirements, manufacturing capabilities, and SCM preferences. It also contains analysis on market growth, M&As, financial updates, upcoming facilities and more!

It provides readers a closer look into companies such as Chugai, Tessa Therapeutics, Daewong Pharm, Eutilex, Carmine Therapeutics, Sumitomo Dainippon, Unicocell Biomed, JW Creagene, Takara Bio and more!

Table of Contents

Section 1

  • Preface
  • Report Scope & Data Coverage
  • IMAPAC's Research Methodology

Section 2 - Company-Wise Analysis

  • Company Overview
  • GMP Certifications
  • Facilities' Size, Equipment, Capabilities etc.
  • Expansion Plans
  • Current Product Pipeline
  • Stage of Development
  • Production Capacity
  • Platform Technologies
  • Product Temperature Requirements
  • Preferred Delivery and SCM methods
  • Partnerships & Collaborations
  • Financial Performance
  • Company Highlights, News & Updates
  • Interviews

Section 3: Region-Wise Data & Analysis {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}

  • Distribution of Cell & Gene Therapy Companies
  • Targeted Disease Types
  • Stage of clinical trial phase
  • Allogenic vs Autolog0us Therapies
  • Targeted Antigens

Section 4: Our Other Reports

  • Bibiliography
  • Disclaimer
  • About Us
  • Our Other Reports

List of Tables and figures

REGIONS COVERED IN ASIA PACIFIC

  • FIGURE 1: TOP 60 CELL AND GENE THERAPY KEY PLAYERS FROM ASIA PACIFIC REGIONS

CHINA

  • FIGURE 2: STAGE OF DEVELOPMENT OF CELL THERAPY IN GREATER CHINA
  • FIGURE 3: REGULATORY APPROVAL IN THE REGION
  • FIGURE 4: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
  • FIGURE 5: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION JAPAN
  • FIGURE 6: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
  • FIGURE 7: REGULATORY APPROVAL IN THE REGION
  • FIGURE 8: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
  • FIGURE 9: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

KOREA

  • FIGURE 10: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
  • FIGURE 11: REGULATORY APPROVAL IN THE REGION
  • FIGURE 12: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
  • FIGURE 13: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

TAIWAN

  • FIGURE 14: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
  • FIGURE 15: REGULATORY APPROVAL IN THE REGION
  • FIGURE 16: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
  • FIGURE 17: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

AUSTRALIA & SEA

  • FIGURE 18: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
  • FIGURE 19: REGULATORY APPROVAL IN THE REGION
  • FIGURE 20: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
  • FIGURE 21: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION